MOA and CareLineLive to Deepen Collaboration as Part of Accel-KKR Portfolio

AKKR Logo

London, UK – October 8, 2025 — MOA and CareLineLive, both now part of the Accel-KKR portfolio, are pleased to announce their intention to deepen collaboration in the UK care technology sector. This strategic alignment builds upon a longstanding partnership and is expected to deliver enhanced value to healthcare providers across the United Kingdom. Accel-KKR, a leading global software investor,  became a majority investor in CareLineLive in June 2025, and acquired MOA in September 2025.

MOA and CareLineLive have a proven history of working together to support care organisations with innovative technology solutions that advance quality, compliance, and operational efficiency. As members of the Accel-KKR family, the companies will pursue closer integration of their respective platforms, surface more powerful insights, and accelerate the development of new products and services.

The collaboration comes at an important time for the UK care sector. Regulators across the UK, including the Care Quality Commission in England, are placing greater emphasis on providers demonstrating clear evidence of safety, quality and continuous improvement. Providers face rising expectations for audit readiness, performance monitoring and the use of digital systems to support compliance.

MOA already supports services in England and Wales with benchmarking, risk management and compliance tools that provide immediate reporting against peers. These tools enable providers to evidence regulatory compliance, manage risk, and strengthen governance processes. CareLineLive’s care management platform is widely adopted across the UK and offers an integrated solution for scheduling, care delivery and digital record keeping. By working more closely together, the two organisations can help providers meet inspection requirements, streamline reporting and deliver improved outcomes for people receiving care.

Josh Hough, Founder & Managing Director of CareLineLive, commented: “Being part of the Accel-KKR portfolio provides a unique opportunity for CareLineLive and MOA to collaborate more directly. Our shared commitment to empowering care providers with advanced technology and actionable insights will help drive improved outcomes for those delivering care throughout the UK.”

Garry Neale, Chief Executive Officer of MOA, added: “MOA and CareLineLive have established a strong partnership within the UK care sector. As portfolio companies of Accel-KKR, we are well-positioned to further integrate our strengths and accelerate innovation. This collaboration will enable us to provide care providers with the tools and support necessary to deliver exceptional care and achieve operational excellence.”

The collaboration will focus on:

  • Enhanced platform integration to streamline workflows
  • Powerful insights to inform clinical and operational decision-making
  • Accelerated innovation to address the evolving needs of the care sector

Importantly, MOA will continue to work with all other clinical management solutions in the market, maintaining its open and collaborative approach to integration.

About CareLineLive
CareLineLive’s cloud-based all-in-one home care management software improves efficiency, capacity and compliance in home care agencies by digitising workflows and automating processes such as rostering and payroll. Home care agencies can save time and money, and carers spend less time on paperwork allowing them to spend more time delivering better care. CareLineLive is the highest rated home care software company in the UK with an Excellent rating on Trustpilot.

https://carelinelive.com/

About MOA
MOA Benchmarking provides a comprehensive schedule of audits and surveys for Adult Social Care providers to continuous self-assess against the CQC Single Assessment Framework and Fundamental Standards and Regulations. The tools allow for continuous and in-depth insight into providers’ performance against the requirements, supported by extensive benchmarked reporting at all levels of the organisation.

Fully integrated modules for Incident Management (IMS), Risk Management, Plan for Continuous Improvement (PCI), Feedback & Complaints, and Policies & Procedures provide an end-to-end Quality Management framework. This allows organisations to foster a culture of continuous quality improvement, strengthen governance, and ensure that every member of the organisation contributes to, and benefits from, a shared commitment to excellence.

http://www.moabenchmarking.co.uk/

Categories: News

Tags:

Platinum Equity to Acquire Products & Healthcare Services Business from Owens & Minor

Platinum

Standalone P&HS anticipated to benefit from Platinum’s carve-out experience, sector expertise and
commitment to growth

Owens & Minor to retain a 5% equity stake in the business

LOS ANGELES (Oct. 7, 2025) – Platinum Equity announced today that it has entered into a definitive agreement to acquire the Products & Healthcare Services (“P&HS”) segment of Owens & Minor (NYSE: OMI). Owens & Minor will retain a five percent interest in the business.

Headquartered in Richmond, VA, P&HS is a vertically-integrated medical supply distribution platform primarily serving the acute care market. It is a leading national distributor of medical and surgical supplies for hospitals, health systems, and other healthcare providers across the United States.

“We are pleased to provide Owens & Minor a divestiture solution for P&HS and are grateful for the continued partnership. With the support of Platinum’s operational capabilities, we are excited about further enhancing P&HS’s global capabilities to deliver essential products and services when and where its customers need.”

Jacob Kotzubei, Co-President, Platinum Equity

“Owens & Minor has played a vital role in supporting healthcare providers and patients across the country, and we are proud to invest in the future of P&HS,” said Jacob Kotzubei, Co-President of Platinum Equity. “We are pleased to provide Owens & Minor a divestiture solution for P&HS and are grateful for the continued partnership. With the support of Platinum’s operational capabilities, we are excited about further enhancing P&HS’s global capabilities to deliver essential products and services when and where its customers need.”

Platinum Equity has invested in numerous healthcare and supply chain businesses and has 30 years of experience acquiring and operating global businesses that have been part of large corporate entities. In recent years the firm has acquired businesses from firms like Ball Corporation, Caterpillar, Emerson Electric, Ingersoll Rand and Kohler, among others.

“Platinum Equity is the perfect home for the Products & Healthcare Services business,” said Edward A. Pesicka, President & Chief Executive Officer of Owens & Minor. “Platinum’s commitment to building on the customer-centric legacy of the business and to strategically invest to stay at the forefront of the evolving healthcare market will serve all stakeholders very well long into the future.”

Platinum Equity Managing Director Matthew Louie said that P&HS’s profile, combined with favorable macro dynamics, make the opportunity attractive for Platinum Equity’s hands-on operational approach to creating value.

“We believe the aging U.S. population and increasing demand for healthcare services will continue to drive sustainable long-term demand for medical supplies distribution,” said Louie. “We are committed to growing the P&HS business and have strong conviction in its potential as a standalone company. We look forward to working with the team to support its continued growth and operational transformation.”

The transaction is expected to close near the end of the year, subject to regulatory review and other customary closing conditions.

Bank of America and Fifth Third are serving as financial advisors to Platinum Equity on the P&HS acquisition. Gibson, Dunn & Crutcher LLP is serving as legal advisor, Willkie Farr & Gallagher LLP is serving as debt financing counsel, and Latham & Watkins LLP is serving as special regulatory counsel to Platinum Equity on the transaction.

Citi and Wells Fargo are acting as financial advisors to Owens & Minor. Kirkland & Ellis is serving as Owens & Minor’s legal advisor.

About Platinum Equity

Founded in 1995 by Tom Gores, Platinum Equity is a global investment firm with approximately $50 billion of assets under management and a portfolio of approximately 60 operating companies that serve customers around the world. Platinum Equity specializes in mergers, acquisitions and operations – a trademarked strategy it calls M&A&O® – acquiring and operating companies in a broad range of business markets, including manufacturing, distribution, transportation and logistics, equipment rental, metals services, media and entertainment, technology, telecommunications and other industries. Over the past 30 years Platinum Equity has completed more than 500 acquisitions.

Categories: News

Tags:

Peli BioThermal Announces Acquisition to Expand Cold Chain Logistics Solutions and Advance Cryogenic Cell and Gene Therapy Transport

Platinum

Acquisition strengthens portfolio, accelerates innovation for customers, and expands reach to new markets

Maple Grove, MN – October 7, 2025 – Peli BioThermal, a global leader in temperature-controlled logistics solutions, today announced the acquisition of Evo from BioLife Solutions, further expanding its leading portfolio of products, services, and technology across the pharmaceutical value chain. The Evo portfolio includes cryogenic shippers and the evoIS® technology platform, designed to meet the rigorous demands of the rapidly growing Cell and Gene Therapy (C&GT) sector.

This acquisition strengthens Peli BioThermal’s ability to deliver a full spectrum of cold chain solutions, providing a more complete range of options to existing customers while creating opportunities to engage with new pharmaceutical, biopharmaceutical, and clinical supply customers. Current Evo users will gain added convenience and integration by sourcing solutions directly through Peli BioThermal, while the Evo product line itself will benefit from accelerated development, innovation, and scale—delivering enhanced value across the expanded customer base.

“Evo will allow Peli BioThermal to offer a full spectrum of temperature-controlled solutions, which will help the company deepen its relationship with existing customers and open access to new high-growth end markets.”

Jacob Kotzubei, Co-President and Matthew Louie, Managing Director, Platinum Equity

The addition of Evo products is particularly significant for the Cell and Gene Therapy market, where cryogenic transport, precision, reliability, and flexibility are paramount for delivering life-saving therapies to patients.

“The addition of Evo is a strategic step forward that rounds out our solutions portfolio and reinforces our commitment to solving our customers’ toughest cold chain challenges,” said Sam Herbert, CEO, Peli BioThermal. “Peli BioThermal customers will gain greater choice and convenience, while Evo customers will benefit from access to our global expertise and service network—ensuring both groups are better supported as their needs grow. BioLife Solutions, and SAVSU before that, have done a fantastic job innovating in a complex market and have been fantastic stewards of this business.  In this next chapter, we will devote our substantial capabilities and further resources to expand and innovate at an accelerated pace.”

The Evo portfolio will integrate well into Peli BioThermal’s offering, joining flagship solutions such as Crēdo™ reusable shippers, NanoCool™ systems, and the recently launched Crēdo Vault™ bulk shipper and Vēro One™ single-use dry ice shipper. With this addition, customers gain expanded flexibility in choosing the right solution for their specific needs—whether optimizing for sustainability, performance, or operational simplicity.

The transaction is Peli BioThermal and Pelican Products’ second add-on acquisition since the Company was acquired by Platinum Equity.

“Evo will allow Peli BioThermal to offer a full spectrum of temperature-controlled solutions, which will help the company deepen its relationship with existing customers and open access to new high-growth end markets,” said Platinum Equity Co-President Jacob Kotzubei and Managing Director Matthew Louie in a joint statement. “Our commitment to investing in Peli BioThermal is creating considerable momentum right now and we are excited about the direction in which the business is headed.”

The Bruce Township, MI operations and team associated with Evo will continue as part of Peli BioThermal, helping ensure continuity of expertise and customer support while leveraging Peli BioThermal’s global resources to scale growth.

To learn more about Peli BioThermal’s expanded portfolio and how it supports Cell and Gene Therapy logistics, visit www.pelibiothermal.com.

About Peli BioThermal
Peli BioThermal is the global leader in temperature-controlled logistics solutions, delivering a comprehensive portfolio of single-use and reusable products and services for the life sciences industry. Backed by Peli’s decades-long reputation for dependability, quality, and innovation, Peli BioThermal solutions help protect life-saving medicines as they move through the global cold chain. For more information, visit www.pelibiothermal.com.

Categories: News

Tags:

AtaCor Medical Secures $75M Financing to Support the Pivotal U.S. Study of its Extravascular ICD (EV-ICD) System

Arboretum

The novel design of AtaCor’s Atala™ lead aims to provide reliable sensing, antitachycardia pacing (ATP), and shock therapies with no hardware placed in the heart or vasculature

SAN CLEMENTE, Calif.Oct. 6, 2025 /PRNewswire/ — AtaCor Medical, Inc., a privately-held medical device company focused on transforming cardiac rhythm management systems, announced today that it has entered into a financing of up to $75 million. The proceeds will fund the company’s U.S. FDA Pivotal Study evaluating AtaCor’s parasternal extravascular implantable cardioverter-defibrillator (EV-ICD) system for the treatment of life-threatening ventricular tachyarrhythmias.

“There is a clear and growing need for extravascular ICD systems that combine a straightforward implant procedure with the ability to deliver the full spectrum of tachyarrhythmia therapies using a small pulse generator,” said Rick Sanghera, Chief Executive Officer of AtaCor Medical. “AtaCor is poised to meet that need. We are proud to close this financing round and excited to initiate our pivotal trial next year.”

 

AtaCor’s EV-ICD system consists of the Atala™ lead and an implantable pulse generator. The Atala™ lead is implanted via a small left parasternal incision, positioned through the rib space with electrodes placed against the pericardium, outside of the heart and vasculature.  The pulse generator can be placed in either a lateral or pectoral subcutaneous device pocket, representing a novel option for EV-ICD systems. This unique EV-ICD system aims to deliver the benefits of defibrillation and antitachycardia pacing without the long-term risks associated with intravascular or intracardiac leads.

“The AtaCor team is developing a meaningful solution for patients, while protecting the integrity of the heart for future interventions,” commented Maria Berkman, Chair of the AtaCor Board of Directors.  “The Board is delighted to see this infusion of capital in support of AtaCor’s pivotal trial, bringing this important technology one step closer to the bedside.”

AtaCor recently completed enrollment of its ASCEND EV Pilot Study, with initial results accepted for presentation at the upcoming Asia Pacific Heart Rhythm Society (APHRS) meeting this November in Yokohama, Japan. Building on these initial results, AtaCor plans to launch the ALARION EV Pivotal Study in the United States and Europe in 2026, which aims to evaluate the safety and efficacy of the parasternal EV-ICD system and support global regulatory submissions.

The AtaCor EV-ICD Lead System is under development exclusively for investigational use and is not approved for sale in any geography.

About AtaCor Medical, Inc.

AtaCor Medical is transforming cardiac pacing and defibrillation with its proprietary extravascular ICD (EV-ICD) system. The novel design provides the full range of therapeutic capabilities of traditional implantable defibrillators, including defibrillation and antitachycardia pacing, without placing hardware inside the heart or vascular system. AtaCor’s technology both preserves future cardiac treatment options and overcomes key limitations of existing ICD systems.

AtaCor venture investors include Arboretum Ventures, Broadview Ventures, Longview Ventures, Hatteras Venture Partners, Catalyst Health Ventures, and BayMed Venture Partners.

For more information, please visit www.atacor.com.

SOURCE AtaCor Medical Inc.

Categories: News

Tags:

CapMan Buyout exits Pharmia to Labomar

Capman

CapMan Buyout exits Pharmia to Labomar

Funds managed by CapMan Buyout have sold Pharmia Holding Oy, a leading Finnish contract manufacturer of dietary supplements and medical devices, to Labomar.

CapMan invested in Pharmia in 2021 and has since focused on growing the company’s business and market position in the Nordics. Today, the company is the leading contract manufacturer within dietary supplements and medical devices in the Nordics with a turnover of approximately 20 million euros and 85 employees. The company’s growth has been driven by a strategic focus on medical devices and probiotics, while simultaneously investing in R&D capabilities and operational efficiency improvements.

“During CapMan Buyout’s ownership period, Pharmia has successfully executed its growth strategy. I want to thank Pharmia’s management and personnel as well as my board colleagues for making this a successful investment. I am convinced that Labomar is the right partner for supporting the growth of Pharmia in the future,” says Anders Björkell, Partner at CapMan Buyout.

“I want to thank CapMan for their strong support over the past years. As a next step we are thrilled to be part of the Labomar family. This acquisition marks a strategic step forward in our mission to expand our footprint in the Nordic region and strengthen our capabilities in the development of high-quality food supplements and medical devices. Labomar’s expertise and values align seamlessly with ours, and together we look forward to driving innovation and delivering even greater value to our partners and customers,” comments Petteri Laaksomo, CEO of Pharmia.

Labomar is a leading European manufacturer of food supplements, medical devices and functional cosmetics, and is owned by Charterhouse Capital Partners. The company is headquartered in Italy with operations in Spain and Canada as well.

“We are proud of this new acquisition. Pharmia is a solid and well-structured company, with an approach and vision that we immediately recognised as being closely aligned with those of Labomar. The know-how and experience of its team represent an added value that will further contribute to the growth of our Group. The integration of Pharmia will also allow us to strengthen our presence in a strategically important geographic market and to consolidate our position in a key sector such as probiotics, thereby creating new synergies and further expanding our offering,” says Walter Bertin, founder and CEO of Labomar.

For more information, please contact:

Anders Björkell, Partner, CapMan Buyout, +358 40 537 7566

Petteri Laaksomo, CEO, Pharmia, +358 50 552 5255

About CapMan

CapMan is a leading Nordic private asset expert with an active approach to value creation and 6.5 billion euros in assets under management. As one of the private equity pioneers in the Nordics we have developed hundreds of companies and assets creating significant value for over three decades. Our objective is to provide attractive returns and innovative solutions to investors by enabling change across our portfolio companies. An example of this is greenhouse gas reduction targets that we have set under the Science Based Targets initiative in line with the 1.5°C scenario and our commitment to net-zero GHG emissions by 2040. We have a broad presence in the unlisted market through our local and specialised teams. Our investment strategies cover real estate and infrastructure assets, real asset debt, natural capital and minority and majority investments in portfolio companies. We also provide wealth management solutions. Altogether, CapMan employs around 200 professionals in Helsinki, Jyväskylä, Stockholm, Copenhagen, Oslo, London, Luxembourg, and Düsseldorf. We are listed on Nasdaq Helsinki since 2001. Learn more at www.capman.com.

About Pharmia

Pharmia is Finland’s leading contract manufacturer specialised in the development and manufacture of food supplements and medical devices (CE-marked products). Pharmia enhances people’s well-being by creating innovative solutions for their customers, which they produce with a concept “from idea to product”. Pharmia’s passion for well-being guides them to be more than just a contract manufacturer – they are a partner that implements and enables their customers’ success. https://pharmia.fi/en/.

Categories: News

Tags:

BeSound: Diagnosing Masses for the Masses

Kindred Ventures

Our Investment in BeSound

Breast cancer screening is broken. Mammograms, invented in the 1950s, remain the dominant tool despite their limitations. They miss 40% of breast cancers in women with dense breast tissue. The process itself is slow and fragmented: book a doctor’s appointment, wait weeks, undergo a manual exam, then a screening image, then a diagnostic image. For many women, this means weeks of anxiety while answers remain out of reach. The FDA recently updated its guidelines requiring providers to notify women with dense breasts that mammograms may not be enough, sending 40 million women a letter that underscores the shortcomings of today’s system.

BeSound is building an alternative: AI-powered ultrasound that collapses weeks of steps into a single visit. By pairing FDA-approved photo-acoustic ultrasound machines with proprietary AI, BeSound delivers precise functional imaging tailored to each woman’s biology. Unlike mammograms, BeSound delivers answers in hours and has been shown in real-world studies to reduce unnecessary biopsies by up to 75%.

That vision is why we’re excited be co-leading BeSound’s $6.76 million seed alongside Overwater Ventures, Muse Capital, and Lux Capital.

Why We Invested

After an hour with Bailey Renger, we were immediately struck by her unusual background. Her technical expertise, knack for brand, and intuition for the changing shape of healthcare present a rare triple threat. Bailey began her career in science, working in an optics lab, at NASA, and at Harvard in quantum computing before starting a PhD in physics at Brown. But during that time, she faced a medical crisis: “I always wanted to be a physics professor… but when I started experiencing severe pain, my doctors told me it was just cramps. I pushed for an ultrasound, and they found a tumor in my ovary. Then I had to wait months for an MRI. That gap in care was the catalyst for me leaving my PhD to start this company.”

Her story underscores why she is so close to the problem. With one in eight women expected to face breast cancer, Bailey’s blend of scientific training and lived urgency gives BeSound a rare edge. The company is positioned to deliver fast, accurate, and scalable diagnostics—offering hope to millions.

Looking Ahead

BeSound is launching first in Los Angeles with its inaugural West Hollywood location, where women can book same day appointments starting at $349. The company is expanding rapidly, including New York in the coming months, bringing FDA approved technology, hospital grade precision, and expert reviewed results within 24 hours.

In the near future, breast cancer screening will shift from decades-old, one size fits all mammograms to AI-powered functional imaging that adapts to each woman’s biology. The future isn’t just about finding cancers earlier, it’s about giving women fast, precise answers, and building an experience that puts them at the center of care.

Join the waitlist at BeSound.

Categories: News

Tags:

Accel-KKR Acquires MOA, Expanding Innovation in Aged Care and Clinical Management Technology

AKKR Logo

Acquisition Unlocks New Collaboration Opportunities with Health Metrics

Brisbane & Melbourne, AUS – September 29, 2025 — Accel-KKR, a global technology-focused private equity firm, has officially acquired MOA, a leading quality improvement platform for aged care, retirement living, and disability service providers across Australia. This acquisition marks a continuation of Accel-KKR’s healthcare technology portfolio and opens the door to deeper collaboration between MOA and fellow portfolio company and enterprise healthcare management provider, Health Metrics.

As part of the Accel-KKR family, MOA and Health Metrics will explore ways to integrate their platforms to deliver enhanced clinical and operational management solutions to care providers. Health Metrics, known for its enterprise-grade software platform eCase, serves organisations that are responsible not only for delivering care, but also for ensuring effective governance, regulatory compliance, and transparency.

“Now that we’re all part of the Accel-KKR portfolio, Health Metrics is excited to work directly with MOA to unlock greater value for our customers,” said Paul Brindle, CEO of Health Metrics. “By combining MOA’s advanced analytics with our eCase clinical, regulatory and compliance platform, providers will be able to gain a 360° view of resident outcomes, clinical risks, and continuous improvement opportunities.

The collaboration aims to deliver:

  • Enhanced clinical and operational insights through shared data and analytics
  • Smarter decision-making and seamless compliance for care providers
  • Richer platform integration
  • Improved data consolidation across platforms

Both teams are committed to partnership models and new product innovations that use risk insights to better inform workflows for carers and strengthen provider compliance.

Importantly, MOA will continue to work with all other clinical management solutions in the market, maintaining its open and collaborative approach to integration.

“This collaboration between MOA and Health Metrics reflects our commitment to investing in technologies that empower providers with deeper insights, seamless compliance, and smarter decision-making,” said Maurice Hernandez, Managing Director at Accel-KKR.

“We’re proud of the impact MOA has had in supporting aged care and disability providers across Australia,” said Garry Neale, CEO of MOA. “Joining the Accel-KKR portfolio and collaborating with Health Metrics allows us to accelerate innovation and deliver even greater value to care providers.”

About Accel-KKR

Accel-KKR is a technology-focused investment firm with over $23 billion in cumulative capital commitments. The firm focuses on software and tech-enabled businesses, well-positioned for topline and bottom-line growth. At the core of Accel-KKR’s investment strategy is a commitment to developing strong partnerships with the management teams of its portfolio companies and a focus on building value alongside management by leveraging the significant resources available through the Accel-KKR network. Accel-KKR focuses on middle-market companies and provides a broad range of capital solutions, including buyout capital, minority-growth investments, and credit alternatives. Accel-KKR also invests across various transaction types, including private company recapitalizations, divisional carve-outs, and going-private transactions. Accel-KKR’s headquarters is in Menlo Park, with offices in Atlanta, Chicago, London, and Mexico City. Visit accel-kkr.com for more information.

About MOA

MOA Benchmarking provides a comprehensive schedule of audits and surveys for self-assessment against ACQS, ARVAS, and NDIS standards, for almost 2,000 aged and community care, retirement living, and disability support services. We also provide collection tools, pre-submission data-quality checking services, and GPMS upload services, for nearly half of all residential aged care services under the National Aged Care Mandatory Quality Indicator Program (NACMQIP).

Fully integrated modules for Incident Management (IMS), Risk Management, Plan for Continuous Improvement (PCI), Feedback & Complaints, and Policies & Procedures provide an end-to-end Quality Management framework. This allows organisations to foster a culture of continuous quality improvement, strengthen governance, and ensure that every member of the organisation contributes to, and benefits from, a shared commitment to excellence. www.moa.com.au

About Health Metrics

Health Metrics is a leading provider of enterprise software for aged care and disability service providers. Its flagship platform, eCase, helps organisations streamline operations, ensure compliance, and deliver high-quality care through integrated digital solutions.  www.healthmetrics.com.au

Categories: News

Tags:

New York Cancer & Blood Specialists (NYCBS) Partners with OncoveryCare to Launch Cancer Survivorship Care

.406 Ventures

OncoveryCare’s survivorship-trained clinicians will treat the chronic and late-effects of cancer treatment to help bring comprehensive care to New York Cancer & Blood Specialists’ cancer survivor population.

 

RIDGE, NY / ACCESS Newswire / September 24, 2025 / New York Cancer & Blood Specialists (NYCBS), one of the nation’s leading community oncology practices, today announced a partnership with OncoveryCare to provide personalized, ongoing care to the NYCBS survivor population. Beginning today, OncoveryCare will work alongside NYCBS oncologists to treat the chronic and late effects of cancer treatment and provide comprehensive cancer follow-up care for NYCBS patients.

As cancer diagnoses increase and mortality rates fall with improvements in treatment, survivorship has become one of cancer care’s most urgent priorities. By 2040, the number of cancer survivors in the United States is expected to reach 26 million – up from 18 million in 2022. At the same time, cancer is increasingly diagnosed at younger ages, leaving survivors to manage its effects for decades. Survivorship care addresses the full spectrum of needs beyond treatment – including managing treatment toxicities, chronic co-morbidities, and mental health. Integrating survivorship into oncology ensures patients receive continuous, comprehensive care.

Through this collaboration, OncoveryCare will deliver comprehensive survivorship care, including integrated medical and behavioral healthcare, to help cancer survivors fully engage in life after cancer. OncoveryCare’s clinical team comprises survivorship-trained Advanced Practice Providers and Licensed Clinical Social Workers with extensive experience in medical oncology, who treat survivorship-related conditions such as fatigue, joint pain, sexual dysfunction, insomnia, anxiety, and more. OncoveryCare clinicians are integrated as part of the broader oncology team – working in close collaboration with the patient’s existing care team.

Dr. Jeff Vacirca, CEO of NYCBS and Co-founder of OneOncology, said “Cancer survivorship is one of the most important frontiers in oncology. Our partnership with OncoveryCare ensures that our patients don’t just survive cancer, but truly thrive in life after treatment. Together, we are setting a new standard for comprehensive survivorship care that addresses every aspect of a patient’s well-being.”

“Cancer doesn’t end when treatment does, and neither should care,” said Dr. MaryAnn Fragola, Chief of Wellness Services at NYCBS. “Through our partnership with OncoveryCare, we are strengthening our commitment to whole-person, patient-centered care by addressing the long-term medical, emotional, and on-going needs of survivors and their loved ones.”

Hil Moss, Co-Founder and CEO of OncoveryCare, said “New York Cancer & Blood Specialists is an innovative leader in oncology, and we’re thrilled to launch a partnership that will transform care for survivors in New York.” Dr. Justin Grischkan, Co-Founder and Chief Medical Officer at OncoveryCare, added, “We are inspired by NYCBS’s commitment to providing comprehensive survivorship care to their patients.”

About New York Cancer & Blood Specialists

New York Cancer & Blood Specialists is a leading oncology practice dedicated to providing world class, patient-centered, and affordable care to individuals with cancer and blood disorders throughout New York State. With locations across Long Island, New York City, and Upstate New York, our mission is to bring world-class cancer care close to home, where patients can heal with the support of family and community.

About OncoveryCare

OncoveryCare delivers comprehensive, whole-person care to cancer survivors. As the population of survivors grows rapidly alongside advances in medicine, OncoveryCare provides the personalized, longitudinal care that cancer survivors need to lead happier, healthier lives. Founded by a breast cancer survivor and a physician, OncoveryCare deploys a survivorship-trained clinical team to treat the chronic and late-effects of each survivor’s cancer treatment and equip survivors with the tools they need to manage their survivorship journey.

OncoveryCare is backed by leading investors and oncology stakeholders, including .406 Ventures, Tennessee Oncology’s McKay Institute, F-Prime, and Oncology Ventures. Learn more at www.oncoverycare.com, and follow us on LinkedIn and Instagram @oncoverycare.

Media Contact
Chloe Baldwin
Senior Manager, Community & Marketing
chloe@oncoverycare.com

Categories: News

Tags:

Vivecti Group and Sana Einkauf join forces to create a leading technology-driven procurement alliance in European healthcare

Nordic Capital
  • Combination strengthens position of hospitals, practices, and care homes in a consolidating market facing major transformation
  • Bundling of demand volume and innovation capacity creates efficiency gains that strengthen both healthcare providers and industry
  • Consistent deployment of digital solutions aims to optimize processes, accelerate workflows, and sustainably improve quality of supply in the healthcare system

Berlin/Ulm, Munich (Germany), 19 September 2025 – Vivecti Group and Sana Kliniken AG are entering into a strategic partnership: Vivecti is acquiring the procurement alliance of Sana Kliniken AG, which serves more than 1,500 healthcare facilities in Germany and Switzerland. Simultaneously, Sana Kliniken AG will acquire a 21 percent stake in Vivecti Group, continuing to support the company’s success as a partner. The combination creates a leading, technology-oriented procurement alliance with innovative products and services for hospitals and other healthcare providers in the European healthcare space. Completion of the transactions is subject to customary regulatory approvals.

The German healthcare system faces significant challenges: While patient numbers stagnate, material costs continue to rise. At the same time, hospitals confront a highly consolidated, internationally operating supplier landscape. To ensure reliable supply and achieve economically viable prices under these conditions, high-performing procurement alliances and digitally controlled processes are becoming increasingly important. This is precisely where the Vivecti-Sana alliance comes in: It bundles demand volume, innovation capacity, and digital expertise, creating efficiency gains that strengthen both healthcare providers and industry, thereby sustainably supporting the healthcare system.

“Healthcare needs strong partnerships in a consolidating market facing transformation. Together with Sana Einkauf, we are laying the foundation for sustainable economic viability and innovative solutions that offer genuine added value to our customers. We are consistently continuing our successful digitalization course: Through coordinated exchange and intelligent analysis of structured data, we create transparency, enhance service quality, and optimize the entire supply process – to the benefit of both healthcare providers and industry,” says Prof. Dr. Benjamin I. Behar, CEO of Vivecti Group.

“With this partnership, we are following our proven strategy: working with partners to continuously improve healthcare supply for patients in a sustainable and forward-looking manner – while remaining part of an international network that guarantees security of supply and innovation. In addition to our long-standing procurement expertise, we will primarily contribute our experience and perspectives as a leading hospital group and customer of procurement services to the partnership,” explains Thomas Lemke, CEO of Sana Kliniken AG.

A Strong Partner for Healthcare Providers and Industry

Vivecti Group, headquartered in Berlin/Ulm, was founded under the name Prospitalia as a procurement group for hospitals. Over the years, the company has evolved into an integrated service provider for inpatient and outpatient healthcare providers and, together with Prospitalia, today comprises ten specialized group companies, including PCM, Wawibox, h-trak, and CoSolvia. As a comprehensive performance partner and digitalization pioneer, Vivecti supports its customers with procurement services and software, professional management and central services, as well as specialized consulting offerings.

Through the Sana procurement alliance, affiliated hospitals and healthcare facilities currently source goods worth approximately four billion euros under conditions negotiated by Sana Einkauf & Logistik GmbH with industry partners. The offering encompasses medical devices, consumables, capital goods, as well as pharmaceuticals and laboratory supplies. With integration into Vivecti Group, a total volume of more than seven billion euros emerges – creating one of Europe’s largest procurement alliances, from which numerous healthcare providers in Germany, Austria, and Switzerland will benefit in the future. Higher procurement volumes secure low price levels and thus comprehensively relieve the healthcare system. Simultaneously, combining both companies’ supplier partnerships leads to a more extensive product portfolio at competitively negotiated prices.

Together with Sana Einkauf, Vivecti will employ approximately 700 staff members and serve over 6,000 healthcare providers as customers across European healthcare. The goal of this step is to relieve economic pressure on hospitals, practices, and care homes, increase security of supply, and consistently advance digital innovations in procurement.

Sana’s hospital full-service supply (KVV) will remain a direct part of Sana Hospital Group and continue to supply over 150 owned and cooperating facilities from seven logistics centers with medical products – from ordering to modular supply to invoice processing. This preserves the proven structure and ensures security of supply and stability for the future.

Hospitals and Industry Benefit from Digital Competence

For affiliated hospitals, the combination opens a series of concrete advantages: They benefit from a strengthened position in procurement negotiations and from reliable supply – even during times of fragile supply chains. More efficient, digitally supported procurement and logistics processes provide additional relief. Simultaneously, the expanded network enables faster exchange of knowledge and best practices as well as comprehensive consulting in strategic supplier and category management.

Following the combination, there will be a particular focus on the digital competence that Vivecti brings to the partnership. Through consistent deployment of digital solutions, processes are to be optimized, workflows accelerated, and quality of supply in the healthcare system sustainably improved. AI-supported applications for procurement and logistics are to be used on a shared data basis – from master data management and data mapping to scanner-based warehouse management systems. The result: greater transparency, more efficient materials management, and strategically aligned procurement optimization.

Strengthening Outpatient Care

An important area of action is strengthening outpatient care – and thus supporting the politically demanded shift from inpatient treatments to the outpatient sector. Lean, digital processes and improved procurement conditions create the prerequisites for this. Vivecti already supports outpatient healthcare providers today – with intuitive materials management solutions and a digital marketplace for professional procurement, as well as with transparency and centrally negotiated procurement volumes that enable price advantages.

 

About Vivecti Group
Vivecti Group is an integrated, technology-supported healthcare partner. The portfolio encompasses procurement, managed services, and consulting, supported by proprietary platforms, data analytics solutions, and software tools. Under the holding company umbrella, specialized companies operate including Prospitalia, Pro Care Management, Wawibox, miralytik, h-trak, WMC/WMCF, Hospital Management Group, and CoSolvia. With approximately 550 employees, Vivecti generated revenue of 145 million euros in 2024.

About Sana Kliniken AG
Sana Kliniken AG is a leading integrated healthcare service provider in the German-speaking region. Comprehensive healthcare for four million patients annually extends from prevention services to outpatient and inpatient care to aftercare, rehabilitation, and the provision of medical aids and devices. These services are delivered nationwide across approximately 50 hospitals, 58 MVZ companies with about 550 physician positions, as well as over 60 medical supply stores and prevention practices combined. Additionally, Sana offers B2B services, including services and consulting for external hospitals, particularly in medical technology and management contracts. In 2024, approximately 41,500 employees generated revenue of 3.6 billion euros. The owners of Sana Kliniken AG, founded in 1976, are 24 private health insurance companies.

 

Media contacts:

Vivecti:

Harald Domke
FGS Global
Tel: +49 171 3383 836
Email: Harald.Domke@fgsglobal.com

Sana Kliniken AG:

Henning Stegmayer
Konzern-Bereichsleiter Unternehmenskommunikation
Tel: +49 151 7463 8356
Email: henning.stegmayer@sana.de

Categories: News

Tags:

TERN Group Raises $24M to Tackle the Global Healthcare Workforce Shortage with AI

RTP Global

Healthcare systems around the world are under immense strain. Demand for care is rising, but workforce capacity isn’t keeping pace. The World Health Organisation predicts that the global healthcare industry will face a shortfall of 18 million healthcare workers by 2030.

Talented and skilled professionals can be deployed to fill these gaps globally, but the systems for healthcare providers to source and relocate global talent are broken. TERN Group offers a solution.

Tackling healthcare problems at scale

After building category-defining businesses across Europe and India, including multinational online used car marketplace Cars24 and PropTech platform IMMO, Avinav Nigam teamed up with Krishna Ramkumar, whose background spans BCG, Nexus Venture Partners and social impact ventures. They launched TERN Group in 2023, inspired by first-hand experiences of the complexities of relocation and migration, as well as the acute skilled talent shortage across the UK, Europe and the Gulf.

Together, they have built the world’s first AI Clinical Workforce Platform. It’s designed for healthcare providers to connect with the global talent they require, with support for sourcing, credentialing, training, and onboarding. TERN Group’s platform vastly improves on the slow and bureaucratic processes typical of international recruitment with a combination of AI-driven workflows and human-led support for training, relocation and settlement.

Importantly, the platform delivers a far more positive experience for both sides of the hiring contract. Healthcare providers access talent fast and more predictably, while talented professionals begin their global careers with dignity and confidence, free of unethical recruitment practices.

Today, London-headquartered TERN Group employs a team of 133 people worldwide across core markets of Germany, UK, UAE, KSA, Japan and the USA. It’s trusted by over 100 healthcare clients and is supporting a global talent pool of 650,000+ professionals across 13 countries.

The future of healthcare talent mobility

Having expanded from one to six core markets this past year, TERN Group is now focused on strengthening its foothold across these markets in addition to accelerating the development of its AI Clinical Workforce platform and ramping up investment in international talent preparation.

We’re delighted to be partnering with Avinav and team through this next phase of growth as an investor in TERN Group’s $24M Series A funding round. You can read more about that raise in Entrepreneur.

Commenting on the raise, Galina Chifina, CEO of RTP Global, said: “At RTP Global, we love backing founders who take on big challenges with heart. Avinav and Krishna are just those founders – solving problems they’ve lived and felt. With TERN, they’re reimagining global talent mobility in a way that’s ethical, scalable, and deeply human, turning it into a powerful, tech-driven solution. We can’t wait to see how TERN will continue to change lives across borders, and we’re delighted to back them on this journey.”

Skilled worker shortages are a truly global challenge. TERN is rising to that challenge with an appropriately global solution that combines AI-driven agility with human support for an end-to-end solution to transform skilled talent mobility.

With AI at its core and scale on the horizon, TERN Group is redefining how healthcare talent moves across the world.